|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Basic Trial Information
Summary The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy. Further Study Information Chemotherapy will be given in accordance with local or regional guidelines but shall include a platinum drug + any topoisomerase inhibitor. Within these limits the study will accept different local variants as long as each centre remains consistent to its declared standard chemotherapy regimen. The recommended regimen is carboplatin or cisplatin plus etoposide q3 weeks for 4 cycles but up to 6 cycles is allowed. Local dosages and dose reduction schedules will be used. Eligibility Criteria Inclusion Criteria: 1. Histologically or cytologically verified SCLC, all stages 2. WHO performance status 0, 1, 2 or 3 3. Age 18 years or older 4. Intention and feasibility to treat with chemotherapy consisting of platinum + topoisomerase inhibitor. 5. Platelets >100 x109 /L 6. Signed informed consent 7. PK (prothrombin complex) INR and APTT within normal ranges. Exclusion Criteria: 1. Prior systemic chemotherapy for lung cancer. 2. Concomitant anticoagulation treatment, except for ASA or clopidogrel 3. Active overt bleeding of clinical importance or at high risk (e.g. earlier observed haemorrhage in a brain metastasis, severe coagulopathy as haemophilia, severe liver dysfunction with impaired coagulation, acute peptic ulcer, and within the last 3 months suffered from intracranial haemorrhage, or surgery in the central nervous system). 4. Any other known contraindication for enoxaparine ( e.g. Hypersensitivity against enoxaparine and its derivatives). 5. Pregnancy or breast-feeding 6. Fertile women not using effective contraceptives or men who do not agree to use effective contraception during the treatment period. 7. Treatment with any other investigational agent, or participation in any other clinical trial. Trial Lead Organizations/Sponsors Lund University Hospital Sanofi-Aventis - US - Bridgewater
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |